Meridian Bioscience (VIVO) 10-Q 5 Aug 22 2022 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Jun. 30, 2022	Jul. 31, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Entity Interactive Data Current	Yes
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Entity Registrant Name	MERIDIAN BIOSCIENCE, INC.
Entity Central Index Key	0000794172
Entity File Number	0-14902
Entity Tax Identification Number	31-0888197
Entity Incorporation, State or Country Code	OH
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Address, Address Line One	3471 River Hills Drive
Entity Address, City or Town	Cincinnati
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	45244
City Area Code	513
Local Phone Number	271-3700
Trading Symbol	VIVO
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock, no par value
Entity Common Stock, Shares Outstanding		43,747,669

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
NET REVENUES	$ 67,771	$ 63,511	$ 267,343	$ 241,692
COST OF SALES	31,043	26,400	112,979	85,261
GROSS PROFIT	36,728	37,111	154,364	156,431
OPERATING EXPENSES
Research and development	6,043	6,083	17,928	17,799
Selling and marketing	8,178	6,209	23,433	19,770
General and administrative	13,149	11,964	46,364	36,827
Acquisition and transaction related costs	4,227	300	4,295	300
Litigation and select legal costs	11,812	438	12,601	2,695
Change in fair value of acquisition consideration	0	(3,563)	0	(5,505)
Total operating expenses	43,409	21,431	104,621	71,886
OPERATING INCOME (LOSS)	(6,681)	15,680	49,743	84,545
OTHER INCOME (EXPENSE)
Interest income	2	0	5	15
Interest expense	(256)	(444)	(969)	(1,450)
RADx grant income	0	0	0	1,000
Other, net	333	59	905	(1,515)
Total other income (expense), net	79	(385)	(59)	(1,950)
EARNINGS (LOSS) BEFORE INCOME TAXES	(6,602)	15,295	49,684	82,595
INCOME TAX PROVISION	736	3,626	12,930	17,845
NET EARNINGS (LOSS)	$ (7,338)	$ 11,669	$ 36,754	$ 64,750
Earnings Per Share Data:
BASIC EARNINGS (LOSS) PER COMMON SHARE	$ (0.17)	$ 0.27	$ 0.84	$ 1.5
DILUTED EARNINGS (LOSS) PER COMMON SHARE	$ (0.16)	$ 0.26	$ 0.83	$ 1.47
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC	43,586	43,334	43,526	43,226
EFFECT OF DILUTIVE STOCK OPTIONS AND RESTRICTED SHARE UNITS	888	763	704	780
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED	44,474	44,097	44,230	44,006
ANTI-DILUTIVE SECURITIES:
Common share options and restricted share units	79	190	188	180

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
NET EARNINGS (LOSS)	$ (7,338)	$ 11,669	$ 36,754	$ 64,750
Other comprehensive income (loss):
Foreign currency translation adjustment	(5,166)	41	(7,044)	3,421
Reclassification of realized gain on cash flow hedge	0	0	(935)	0
Unrealized gain on cash flow hedge	216	9	2,201	469
Reclassification of amortization of gain on cash flow hedge	0	0	0	(154)
Income taxes related to items of other comprehensive income (loss)	(53)	(2)	(310)	(68)
Other comprehensive income (loss), net of tax	(5,003)	48	(6,088)	3,668
COMPREHENSIVE INCOME (LOSS)	$ (12,341)	$ 11,717	$ 30,666	$ 68,418

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$ 36,754	$ 64,750
Non-cash items included in net earnings:
Depreciation of property, plant and equipment	5,009	4,729
Amortization of intangible assets	7,433	6,453
Stock-based compensation	5,006	3,170
Deferred income taxes	2,248	(35)
Estimated litigation costs	10,000	0
Change in fair value of acquisition consideration	0	(5,505)
Change in the following:
Accounts receivable	7,933	(2,363)
Inventories	4,473	(11,831)
Prepaid expenses and other current assets	(1,401)	(1,965)
Accounts payable and accrued expenses	4,800	(2,252)
Income taxes payable	(1,515)	(2,317)
Other, net	(366)	(448)
Net cash provided by operating activities	80,374	52,386
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	(5,138)	(16,407)
Acquisition, net of cash acquired and holdback	(3,750)	0
Payment of acquisition consideration holdback	0	(5,000)
Net cash used in investing activities	(8,888)	(21,407)
CASH FLOWS FROM FINANCING ACTIVITIES
Payment on revolving credit facility	(35,000)	(18,824)
Payment of deferred financing costs	(404)	0
Proceeds from exercise of stock options	2,438	2,939
Employee taxes paid upon stock option exercises and net share settlement of restricted share units	(865)	0
Net cash used in financing activities	(33,831)	(15,885)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	(3,939)	1,404
Net Increase in Cash and Cash Equivalents	33,716	16,498
Cash and Cash Equivalents at Beginning of Period	49,771	53,514
Cash and Cash Equivalents at End of Period	$ 83,487	$ 70,012

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Sep. 30, 2021
CURRENT ASSETS
Cash and cash equivalents	$ 83,487	$ 49,771
Accounts receivable, less allowances of $1,071 and $1,078, respectively	44,911	53,568
Inventories, net	70,105	76,842
Prepaid expenses and other current assets	13,966	12,626
Total current assets	212,469	192,807
PROPERTY, PLANT AND EQUIPMENT, at Cost
Land	976	989
Buildings and improvements	32,917	32,765
Machinery, equipment and furniture	79,939	78,410
Construction in progress	9,049	9,991
Subtotal	122,881	122,155
Less: accumulated depreciation and amortization	79,712	78,941
Property, plant and equipment, net	43,169	43,214
OTHER ASSETS
Goodwill	117,201	114,668
Other intangible assets, net	76,607	84,151
Right-of-use assets, net	6,680	5,786
Deferred income taxes	8,043	8,731
Other assets	1,759	365
Total other assets	210,290	213,701
TOTAL ASSETS	465,928	449,722
CURRENT LIABILITIES
Accounts payable	15,359	11,701
Accrued employee compensation costs	19,697	16,853
Accrued product recall costs	2,359	5,100
Accrued estimated litigation costs	10,000	0
Current operating lease obligations	2,025	1,990
Current government grant obligations	1,200	638
Other accrued expenses	7,632	7,027
Income taxes payable	2,075	3,848
Total current liabilities	60,347	47,157
NON-CURRENT LIABILITIES
Post-employment benefits	2,032	2,253
Long-term operating lease obligations	4,773	3,932
Long-term debt	25,000	60,000
Government grant obligations	4,403	5,176
Long-term income taxes payable	527	469
Deferred income taxes	2,644	1,055
Other non-current liabilities	655	1,378
Total non-current liabilities	40,034	74,263
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY
Preferred stock, no par value; 1,000,000 shares authorized; none issued
Common shares, no par value; 71,000,000 shares authorized, 43,718,576 and 43,361,898 shares issued and outstanding, respectively
Additional paid-in capital	154,241	147,403
Treasury stock, at cost; 9,655 shares	(259)	0
Retained earnings	217,455	180,701
Accumulated other comprehensive income (loss)	(5,890)	198
Total shareholders' equity	365,547	328,302
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 465,928	$ 449,722

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Sep. 30, 2021
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 1,071	$ 1,078
Preferred stock, par value	$ 0	$ 0
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0	$ 0
Common stock, shares authorized	71,000,000	71,000,000
Common stock, shares issued	43,718,576	43,361,898
Common Stock, shares, outstanding	43,718,576	43,361,898
Treasury Stock ,Shares	9,655	9,655

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Shares [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning balance at Sep. 30, 2020	$ 247,629		$ 140,195	$ 0	$ 109,294	$ (1,860)
Beginning balance, Shares at Sep. 30, 2020		43,069,000		0
Conversion of restricted share units and exercise of stock options	2,939		2,939
Conversion of restricted share units and exercise of stock options, Shares		284
Stock compensation expense	3,170		3,170
Net earnings (loss)	64,750				64,750
Foreign currency translation adjustment	3,421					3,421
Hedging activity, net of tax	247					247
Ending balance at Jun. 30, 2021	322,156		146,304	$ 0	174,044	1,808
Ending balance, Shares at Jun. 30, 2021		43,353,000		0
Beginning balance at Mar. 31, 2021	309,473		145,338	$ 0	162,375	1,760
Beginning balance, Shares at Mar. 31, 2021		43,329,000		0
Conversion of restricted share units and exercise of stock options	87		87
Conversion of restricted share units and exercise of stock options, Shares		24,000
Stock compensation expense	879		879
Net earnings (loss)	11,669				11,669
Foreign currency translation adjustment	41					41
Hedging activity, net of tax	7					7
Ending balance at Jun. 30, 2021	322,156		146,304	$ 0	174,044	1,808
Ending balance, Shares at Jun. 30, 2021		43,353,000		0
Beginning balance at Sep. 30, 2021	328,302		147,403	$ 0	180,701	198
Beginning balance, Shares at Sep. 30, 2021		43,362,000		0
Conversion of restricted share units and exercise of stock options	1,573		1,832	$ (259)	0	0
Conversion of restricted share units and exercise of stock options, Shares		357		(10)
Stock compensation expense	5,006		5,006
Net earnings (loss)	36,754				36,754
Foreign currency translation adjustment	(7,044)					(7,044)
Hedging activity, net of tax	956					956
Ending balance at Jun. 30, 2022	365,547		154,241	$ (259)	217,455	(5,890)
Ending balance, Shares at Jun. 30, 2022		43,719,000		(10,000)
Beginning balance at Mar. 31, 2022	374,632		150,985	$ (259)	224,793	(887)
Beginning balance, Shares at Mar. 31, 2022		43,570,000		(10,000)
Conversion of restricted share units and exercise of stock options	1,639		1,639	$ 0
Conversion of restricted share units and exercise of stock options, Shares		149,000		0
Stock compensation expense	1,617		1,617
Net earnings (loss)	(7,338)				(7,338)	0
Foreign currency translation adjustment	(5,166)					(5,166)
Hedging activity, net of tax	163					163
Ending balance at Jun. 30, 2022	$ 365,547		$ 154,241	$ (259)	$ 217,455	$ (5,890)
Ending balance, Shares at Jun. 30, 2022		43,719,000		(10,000)

Nature of Business

Nature of Business	9 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	1. Nature of Business Meridian Bioscience, Inc. (“Meridian” or “the Company”) was formed in 1976 and functions as a fully-integrated life science company with principal businesses in: (i) the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and (ii) the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, various Polymerase Chain Reaction (“PCR”) and isothermal amplification master mixes, and bioresearch reagents used by other diagnostic manufacturers and researchers. Our reportable segments are Diagnostics and Life Science. The Diagnostics segment consists of: (i) manufacturing operations for infectious disease products in Cincinnati, Ohio; Quebec City, Canada; and Modi’in, Israel; (ii) manufacturing operations for blood chemistry products in Billerica, Massachusetts; and (iii) the sale and distribution of diagnostics products domestically and abroad. This segment’s products are used by hospitals, reference labs and physician offices to detect infectious diseases and elevated lead levels in blood. The Life Science segment consists of: (i) manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; North Brunswick, New Jersey; London, England; and Luckenwalde, Germany;

Basis of Presentation

Basis of Presentation	9 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	2. Basis of Presentation The Condensed Consolidated Financial Statements are unaudited and are prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) for interim financial information, and the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of Management, the Condensed Consolidated Financial Statements include all normal adjustments and disclosures necessary to present fairly the Company’s consolidated financial position as of June 30, 2022, and the results of its operations and shareholders’ equity for the three and nine months ended June 30, 2022 and 2021, and cash flows for the nine months ended June 30, 2022 and 2021. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the Company’s fiscal 2021 Annual Report on Form 10-K, It should be noted that the terms revenue and/or revenues are utilized throughout these notes to the Condensed Consolidated Financial Statements to indicate net revenue and/or net revenues. The consolidated results of operations for interim periods are not necessarily indicative of the results to be expected for the full fiscal year. The preparation of these Condensed Consolidated Financial Statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the Condensed Consolidated Financial Statements and the reported amounts of revenues and expenses during the period. Included within these estimates are those related to the ongoing impacts of the COVID-19

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies A summary of the Company’s significant accounting policies is included in Note 1 to the audited consolidated financial statements of the Company’s fiscal 2021 Annual Report on Form 10-K, (a) Recent Accounting Pronouncements – Pronouncements Adopted On October 1, 2021, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes 2019-12”), 2019-12 Pronouncements Issued but Not Yet Adopted as of June 30, 2022 In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting No other new accounting pronouncements recently adopted or issued had or are expected to have a material impact on the Condensed Consolidated Financial Statements. (b) Reclassifications – Certain reclassifications have been made to the prior year Condensed Consolidated Financial Statements to conform to the current year presentation. Such reclassifications had no impact on net earnings (loss) or shareholders’ equity.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	4. Revenue Recognition Revenue Disaggregation The following tables present our net revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics segment only): Net Revenues by Reportable Segment & Geographic Region Three Months Ended June 30, Nine Months Ended June 30, 2022 2021 Inc (Dec) 2022 2021 Inc (Dec) Diagnostics- Americas $ 38,158 $ 24,543 55 % $ 98,322 $ 73,367 34 % EMEA 3,836 6,251 (39 )% 17,042 18,352 (7 )% ROW 415 395 5 % 1,352 1,740 (22 )% Total Diagnostics 42,409 31,189 36 % 116,716 93,459 25 % Life Science- Americas 7,314 7,419 (1 )% 25,833 39,661 (35 )% EMEA 8,200 15,723 (48 )% 70,188 70,084 — % ROW 9,848 9,180 7 % 54,606 38,488 42 % Total Life Science 25,362 32,322 (22 )% 150,627 148,233 2 % Consolidated $ 67,771 $ 63,511 7 % $ 267,343 $ 241,692 11 % Net Revenues by Product Platform/Type Three Months Ended June 30, Nine Months Ended June 30, 2022 2021 Inc (Dec) 2022 2021 Inc (Dec) Diagnostics- Molecular assays $ 4,876 $ 4,383 11 % $ 14,039 $ 13,368 5 % Non-molecular 37,533 26,806 40 % 102,677 80,091 28 % Total Diagnostics 42,409 31,189 36 % 116,716 93,459 25 % Life Science- Molecular reagents 7,743 20,385 (62 )% 79,531 104,016 (24 )% Immunological reagents 17,619 11,937 48 % 71,096 44,217 61 % Total Life Science 25,362 32,322 (22 )% 150,627 148,233 2 % Consolidated $ 67,771 $ 63,511 7 % $ 267,343 $ 241,692 11 % Net Revenues by Disease State (Diagnostics segment only) Three Months Ended June 30, Nine Months Ended June 30, 2022 2021 Inc (Dec) 2022 2021 Inc (Dec) Diagnostics- Gastrointestinal assays $ 22,715 $ 17,844 27 % $ 64,704 $ 48,962 32 % Respiratory illness assays 5,488 3,742 47 % 21,359 12,233 75 % Blood chemistry assays 6,431 4,254 51 % 9,762 13,006 (25 )% Other 7,775 5,349 45 % 20,891 19,258 8 % Total Diagnostics $ 42,409 31,189 36 % $ 116,716 93,459 25 % Royalty Income Royalty income received from a third party related primarily to sales of H. pylori Non-molecular Reagent Rental Arrangements Revenue allocated to the lease elements of Reagent Rental arrangements totaled approximately $1,080 and $950 in the three months ended June 30, 2022 and 2021, respectively, and $2,805 and $2,730 in the nine months ended June 30, 2022 and 2021, respectively. Such revenue is included as part of net revenues in our Condensed Consolidated Statements of Operations.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements To limit exposure to volatility in the LIBOR interest rate, the Company has entered into interest rate swap agreements, which effectively convert the variable interest rate on the outstanding revolving credit facility discussed in Note 12 to a fixed rate. The fair values of the interest rate swap agreements were determined by reference to a third-party valuation, which is considered a Level 2 input within the fair value hierarchy of valuation techniques, and totaled a $1,062 asset and a $203 liability, as of June 30, 2022 and September 30, 2021, respectively. In conjunction with the paydown of $25,000 on the revolving credit facility in March 2022, a $25,000 interest rate swap agreement was terminated, resulting in a gain of $935, which is recorded in other income (expense), net in our Condensed Consolidated Statements of Operations during the nine months ended June 30, 2022. As indicated in Note 6, we acquired EUPROTEIN Inc. of North Brunswick, New Jersey (EUPROTEIN”) on April 30, 2022 and the BreathTek business on July 31, 2021. The fair values of inventories acquired were valued using Level 2 inputs, which included data points that were observable, such as established values of comparable assets and historical sales information (market approach). Identifiable intangible assets, if applicable and specifically the acquired customer relationships, were valued using Level 3 inputs, which are unobservable by nature, and included internal estimates of future cash flows and attrition rates (income approach). Significant increases (decreases) in any of those unobservable inputs, as of the date of the acquisition, in isolation would result in a significantly lower (higher) fair value measurement.

Business Combinations

Business Combinations	9 Months Ended
	Jun. 30, 2022
Business Combinations [Abstract]
Business Combinations	6. Business Combinations On April 30, 2022, we acquired substantially all of the assets of EUPROTEIN for $4,250 in cash, of which $3,750 was paid at closing, with the remainder held back for final closing adjustments, which is recorded in other non-current preliminary basis On July 31, 2021, we acquired the BreathTek business, a urea breath test for the detection of H. pylori and i The Company’s consolidated results for the three and nine months ended June 30, 2022 include approximately $5,500 and $16,600, respectively, of net revenues from BreathTek product sales, which contributed approximately $1,800 and $5,000, respectively, of net earnings. These results, which are reported as part of the Diagnostics segment, include amortization expense related to the customer relationships recorded in the purchase price allocation totaling $479 and $1,439, during the three and nine months ended June 30, 2022, respectively. The following table provides the unaudited consolidated pro forma results for the periods presented as if the BreathTek business had been acquired as of the beginning of fiscal 2021: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Net revenues $ 67,771 $ 69,920 $ 267,343 $ 258,777 Net earnings (loss) (7,338 ) 13,685 36,754 69,737 Based on the nature of the EUPROTEIN business, EUPROTEIN is not expected to contribute materially to net revenues and net earnings (loss) and therefore, no amounts are included in the table above.

Lead Testing Matters

Lead Testing Matters	9 Months Ended
	Jun. 30, 2022
Lead Testing Matters [Abstract]
Lead Testing Matters	7. Lead Testing Matters On September 1, 2021, the Company’s wholly owned subsidiary Magellan announced the expansion of a Class I voluntary recall of its LeadCare test kits for the detection of lead in blood, which it had initiated in May 2021. Customers generally run controls when they receive a new lot of product and report to us when the control results are outside of specified ranges. This process identified certain impacted test kit lots that could potentially underestimate blood lead levels when processing patient blood samples. Although it was initially believed that the root cause of the issue related to the plastic containers used for the treatment reagent, additional studies have indicated that the root cause related to the third-party-sourced cardboard trays that held the treatment reagent containers. Upon correction of the identified supplier issue, shipment of product resumed during February 2022. The Company continues to work closely with the FDA in its execution of the recall activities, which include notifications to customers and distributors, and providing instructions for the return of impacted test kits. The evaluation of the recall and the related notification process are ongoing. Of the $5,100 estimated and accrued as of September 30, 2021, to cover the estimated costs of the recall, $2,359 remains accrued and is reflected in the Condensed Consolidated Balance Sheet as of June 30, 2022. Anticipated recall-related costs, which primarily include product replacement and/or refund costs, mailing/shipping costs, attorneys’ fees, and other miscellaneous costs are estimated based upon the most recent information available. Information utilized in the accrual estimation process includes observable inputs such as customer on-hand As previously disclosed, on April 17, 2018, the Company’s wholly owned subsidiary Magellan received a subpoena from the U.S. Department of Justice (“DOJ”) regarding its LeadCare product line. The subpoena outlined documents to be produced, and the Company is cooperating with the DOJ in this matter. The Company maintains rigorous policies and procedures to promote compliance with applicable regulatory requirements and is working with the DOJ to promptly respond to the subpoena, including responding to additional information requests that have followed receipt of the subpoena in April 2018. The Company has executed tolling agreements to extend the statute of limitations. In March and April 2021, the DOJ issued two subpoenas, both to former employees of Magellan, calling for witnesses to testify before a federal grand jury related to this matter. In September and October 2021, the DOJ issued additional subpoenas to individuals seeking testimony and documents in connection with its ongoing investigation. It is the Company’s understanding that multiple witnesses have testified before the federal grand jury and the DOJ’s investigation is ongoing. Discussions continue with the DOJ to explore resolution of the matter. As of June 30, 2022, in accordance with the applicable accounting guidance, the Company accrued $10,000 as an estimate of the cost to settle the LeadCare legal matter, which is reflected in litigation and select legal costs within the Condensed Consolidated Statements of Operations for the three and nine months ended June 30, 2022. The Company cannot predict when the investigation will be resolved or the outcome of the investigation, and the ultimate resolution of the LeadCare legal matter may exceed the amount accrued at June 30, 2022 and could be material to the Condensed Consolidated Statement of Operations. Approximately $1,812 and $438 of expense for attorneys’ fees related to this matter is included in litigation and select legal costs within the Condensed Consolidated Statements of Operations for the three months ended June 30, 2022 and 2021, respectively, and $2,601 and $2,695, for the nine months ended June 30, 2022 and 2021, respectively.

Cash and Cash Equivalents

Cash and Cash Equivalents	9 Months Ended
	Jun. 30, 2022
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	8. Cash and Cash Equivalents Cash and cash equivalents include the following: June 30, September 30, Institutional money market funds $ 1,021 $ 1,020 Cash on hand, unrestricted 82,466 48,751 Total $ 83,487 $ 49,771 Cash equivalents, institutional money market funds, are classified within Level 1 of the fair value hierarchy. Financial instruments classified as Level 1 are based on quoted market prices in active markets. The Company does not adjust the quoted market price for such financial instruments.

Inventories, Net

Inventories, Net	9 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Inventories, Net	9. Inventories, Net Inventories, net, are comprised of the following: June 30, September 30, Raw materials $ 15,920 $ 14,843 Work-in-process 21,492 25,072 Finished goods - instruments 2,259 2,260 Finished goods - kits and reagents 30,434 34,667 Total $ 70,105 $ 76,842

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets, Net	9 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets, Net	10. Goodwill and Other Intangible Assets, Net Goodwill is not amortized but is subject to an annual impairment test. Goodwill has been assigned to reporting units within the reportable segments. The Company assesses the carrying value of goodwill annually, or more often if events or changes in circumstances indicate there may be impairment. Impairment testing is performed at a reporting unit level. During the nine months ended June 30, 2022, goodwill increased $2,533, comprised of: (i) a $411 decrease in Diagnostics segment goodwill; and (ii) a $2,944 increase in Life Science segment goodwill. This overall net increase in goodwill reflects $3,971 of goodwill acquired in the EUPROTEIN acquisition (see Note 6), partially offset by the effects of foreign currency translation. During the three and nine months ended June 30, 2022, the Company did not observe any triggering events or substantive changes in circumstances requiring the need for an interim impairment assessment. A summary of other intangible assets, net, subject to amortization is as follows: June 30, 2022 September 30, 2021 Gross Accumulated Gross Accumulated Manufacturing technologies, core products and cell lines $ 62,291 $ 25,369 $ 62,416 $ 22,633 Trade names, licenses and patents 18,341 10,268 18,489 9,492 Customer lists, customer relationships and supply agreements 54,491 22,941 54,941 19,649 Non-compete 110 48 110 31 Total $ 135,233 $ 58,626 $ 135,956 $ 51,805 The aggregate amortization expense for these other intangible assets was $2,467 and $2,090 for the three months ended June 30, 2022 and 2021, respectively, and $7,433 and $6,453 for the nine months ended June 30, 2022 and 2021, respectively. The estimated aggregate amortization expense for these other intangible assets for each of the fiscal years through fiscal 2027 is as follows: remainder of fiscal 2022 – $2,480, fiscal 2023 – $9,905, fiscal 2024 – $9,900, fiscal 2025 – $9,890, fiscal 2026 – $8,900, and fiscal 2027 – $6,645.

Leasing Arrangements

Leasing Arrangements	9 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Leasing Arrangements	11. Leasing Arrangements The Company is party to several operating leases, the majority of which are related to office, warehouse and manufacturing space. The related operating lease assets and obligations are reflected within right-of-use The lease costs for these operating leases reflected in our Condensed Consolidated Statements of Operations, as well as the right-of-use Three Months Nine Months 2022 2021 2022 2021 Lease costs within cost of sales $ 223 $ 213 $ 676 $ 569 Lease costs within operating expenses 340 390 1,086 1,151 Right-of-use — 381 3,021 1,073 In addition, the Company periodically enters into other short-term operating leases, generally with an initial term of twelve months or less. These leases are not recorded on the Condensed Consolidated Balance Sheets and the related lease expense is immaterial for the three and nine months ended June 30, 2022 and 2021. The Company often has options to renew lease terms, with the exercise of lease renewal options generally at the Company’s sole discretion. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors. The discount rate implicit within our leases is generally not determinable and, therefore, the Company uses its incremental borrowing rate as the basis for its discount rate. The weighted average remaining lease term for our operating leases and the weighted average discount rate used to measure our operating leases were as follows: June 30, September 30, Weighted average remaining lease term 4.0 years 3.6 years Average discount rate 3.5 % 3.2 % Maturities of lease liabilities by fiscal year for the Company’s operating leases were as follows as of June 30, 2022: 2022 (represents remainder of fiscal year) $ 556 2023 2,073 2024 1,696 2025 1,403 2026 829 Thereafter 723 Total lease payments 7,280 Less amount of lease payments representing interest (482 ) Total present value of lease payments $ 6,798 Supplemental cash flow information related to the Company’s operating leases is as follows: Nine Months Ended June 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 1,784 $ 1,611

Bank Credit Arrangements

Bank Credit Arrangements	9 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Bank Credit Arrangements	12. Bank Credit Arrangements The Company maintains a revolving credit facility with a commercial bank in an aggregate principal amount not to exceed $200,000, which expires in October 2026. Outstanding principal amounts bear interest at a fluctuating rate tied to, at the Company’s option, either the federal funds rate or LIBOR, resulting in an effective cost of borrowing of 3.47% and 2.52% on the revolving credit facility during the three months ended June 30, 2022 and 2021, respectively, and 2.55% during each of the nine month periods ended June 30, 2022 and 2021. In light of the interest being determined on a variable rate basis, the fair value of the borrowings under the revolving credit facility at both June 30, 2022 and September 30, 2021, approximates the current carrying value reflected in the Condensed Consolidated Balance Sheets of $25,000 and $60,000, respectively, which is consistent with a level 2 fair value measurement. The revolving credit facility is collateralized by the business assets of the Company’s U.S. subsidiaries and requires compliance with financial covenants that limit the amount of debt obligations and require a minimum level of coverage of fixed charges, as defined in the revolving credit facility agreement. As of June 30, 2022, the Company was in compliance with all covenants.

Contingent Obligations and Non-

Contingent Obligations and Non-Current Liabilities	9 Months Ended
	Jun. 30, 2022
Contingent Obligations and NonCurrent Liabilities Disclosure [Abstract]
Contingent Obligations and Non-Current Liabilities	13. Contingent Obligations and Non-Current In connection with the acquisition of Exalenz Bioscience Ltd. (“Exalenz”) in fiscal 2020, the Company assumed several Israeli government grant obligations. The repayment of the grants, along with interest incurred at varying stated fixed rates based on LIBOR at the time each grant was received, is not dictated by an established repayment schedule. Rather, the grants and related interest are required to be repaid using 3% of the net revenues generated from the sales of BreathID products, with the timing of repayment contingent upon the level and timing of such revenues. In addition, the grants have no collateral or financial covenant provisions generally associated with traditional borrowing instruments. These obligation amounts total $5,603 and $5,814 as of June 30, 2022 and September 30, 2021, respectively, bearing interest at rates ranging from 0.58% to 2.02%. The grant obligations are reflected in the Condensed Consolidated Balance Sheets as follows: June 30, September 30, Current liabilities $ 1,200 $ 638 Non-current $ 4,403 $ 5,176 Additionally, the Company has provided certain post-employment benefits to its former Chief Executive Officer, and these obligations total $1,570 and $1,676 at June 30, 2022 and September 30, 2021, respectively. In addition, the Company is required by the governments of certain foreign countries in which we operate to maintain a level of accruals for potential future severance indemnity. These accruals total $641 and $754 at June 30, 2022 and September 30, 2021, respectively.

National Institutes of Health C

National Institutes of Health Contracts	9 Months Ended
	Jun. 30, 2022
Research and Development [Abstract]
National Institutes of Health Contracts	14. National Institutes of Health Contracts In December 2020, the Company entered into a sub-award SARS-CoV-2 On January 25, 2022, the Company entered into a contract to amend the Company’s second grant contract under the RADx initiative, which was originally effective February 1, 2021. The purpose of the grant is to support the Company’s manufacturing production scale-up COVID-19 24-month COVID-19

Reportable Segment and Major Cu

Reportable Segment and Major Customers Information	9 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Reportable Segment and Major Customers Information	15. Reportable Segment and Major Customers Information The Company’s reportable segments maintain separate financial information for which results of operations are evaluated on a regular basis by the Company’s chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company records the direct costs of business operations to the reportable segments, including allocations for certain corporate-wide costs such as treasury management, human resources and technology, among others. Corporate provides certain executive management and administrative services to each reportable segment. These services primarily include executive oversight by non-segment-specific Reportable segment and corporate information for the interim periods is as follows: Diagnostics Life Science Corporate (1) Eliminations (2) Total Three Months Ended June 30, 2022 Net revenues - Third-party $ 42,409 $ 25,362 $ — $ — $ 67,771 Inter-segment 67 43 — (110 ) — Operating income (loss) 3,278 9,088 (19,084 ) 37 (6,681 ) Goodwill (June 30, 2022) 94,493 22,708 — — 117,201 Other intangible assets, net (June 30, 2022) 76,605 2 — — 76,607 Total assets (June 30, 2022) 347,177 118,786 — (35 ) 465,928 Three Months Ended June 30, 2021 Net revenues - Third-party $ 31,189 $ 32,322 $ — $ — $ 63,511 Inter-segment 100 54 — (154 ) — Operating income (loss) 2,717 16,078 (3,154 ) 39 15,680 Goodwill (September 30, 2021) 94,904 19,764 — — 114,668 Other intangible assets, net (September 30, 2021) 84,149 2 — — 84,151 Total assets (September 30, 2021) 339,208 110,536 — (22 ) 449,722 Nine Months Ended June 30, 2022 Net revenues - Third-party $ 116,716 $ 150,627 $ — $ — $ 267,343 Inter-segment 214 130 — (344 ) — Operating income (loss) 3,104 75,976 (29,407 ) 70 49,743 Nine Months Ended June 30, 2021 Net revenues - Third-party $ 93,459 $ 148,233 $ — $ — $ 241,692 Inter-segment 285 163 — (448 ) — Operating income (loss) 4,400 91,832 (11,754 ) 67 84,545 (1) Includes litigation and select legal costs, and acquisition and transaction related costs of $16,000 and $16,789 in the three and nine months ended June 30, 2022, respectively, and $438 and $2,695 in the three and nine months ended June 30, 2021, respectively. (2) Eliminations consist of inter-segment transactions. A reconciliation of reportable segment operating income to consolidated earnings (loss) before income taxes is as follows: Three Months Nine Months 2022 2021 2022 2021 Operating income: Diagnostics segment $ 3,278 $ 2,717 $ 3,104 $ 4,400 Life Science segment 9,088 16,078 75,976 91,832 Eliminations 37 39 70 67 Total segment operating income 12,403 18,834 79,150 96,299 Corporate operating expenses (19,084 ) (3,154 ) (29,407 ) (11,754 ) Interest income 2 — 5 15 Interest expense (256 ) (444 ) (969 ) (1,450 ) RADx initiative grant income — — — 1,000 Other, net 333 59 905 (1,515 ) Consolidated earnings (loss) before income taxe s $ (6,602 ) $ 15,295 $ 49,684 $ 82,595 Transactions between reportable segments are accounted for at established intercompany prices for internal and management purposes, with all intercompany amounts eliminated in consolidation. Net revenues generated by the Company’s three major Diagnostics segment product families – gastrointestinal, respiratory illnesses and blood chemistry – accounted for 51% and 41% of consolidated net revenues during the three months ended June 30, 2022 and 2021, respectively, and 36% and 31% during the nine months ended June 30, 2022 and 2021, respectively. Individual Diagnostics or Life Science segment customers, including their affiliates, comprising 10% or more of reportable segment net revenues were as follows: Three Months Nine Months 2022 2021 2022 2021 Diagnostics Customer A 7 % 10 % 8 % 11 % Customer B 9 % 11 % 9 % 10 % Customer C 12 % 14 % 11 % 12 % Life Science Customer D 14 % 9 % 7 % 7 % Customer E 1 % 4 % 11 % 12 % Customer F 17 % 3 % 21 % 2 % During the three months ended June 30, 2022 and 2021, no individual Diagnostics segment or Life Science segment customer accounted for 10% or more of consolidated net revenues. During the nine months ended June 30, 2022 and 2021, no Diagnostics segment customer accounted for 10% or more of consolidated net revenues, while one Life Science segment customer (Customer F above) comprised 12% of consolidated net revenues during the nine months ended June 30, 2022, and 1% of consolidated net revenues during the corresponding fiscal 2021 interim period. In addition, during the three months ended June 30, 2022 and 2021, the Life Science segment’s ten largest customers, including their affiliates, accounted for approximately 54% and 46%, respectively, of Life Science segment net revenues, and approximately 20% and 24%, respectively, of consolidated net revenues. During the nine months ended June 30, 2022 and 2021, the Life Science segment’s ten largest customers, including their affiliates, accounted for approximately 58% and 43%, respectively, of Life Science segment net revenues, and 33% and 27%, respectively, of consolidated net revenues. No Diagnostics or Life Science segment customer accounted for greater than 10% of consolidated accounts receivable as of June 30, 2022, while one Diagnostics segment customer (Customer B above) and one Life Science segment customer (Customer D above) accounted for approximately 12% and 10%, respectively, of consolidated accounts receivable as of September 30, 2021.

Income Taxes

Income Taxes	9 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	16. Income Taxes The effective rate for income taxes was approximately (11%) and 26% for the three and nine months ended June 30, 2022, respectively, and 24% and 22% for the three and nine months ended June 30, 2021, respectively. The negative effective rate for the three months ended June 30, 2022 and the increase in effective rates for the nine months ended June 30, 2022, relate primarily to the anticipated non-deductibility

Subsequent Events

Subsequent Events	9 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Event On July 7, 2022, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea (“SDB”), Columbus Holding Company, a Delaware corporation (“Parent”), and Madeira Acquisition Corp., an Ohio corporation and a direct wholly owned subsidiary of Parent (“Merger Sub”). Meridian is informed that SJL Partners, LLC (“SJL”) is currently the sole shareholder of Parent, and SDB together with SJL will be the sole shareholders of Parent as of the closing of the Merger. Pursuant to the Merger Agreement, Merger Sub will merge with and into Meridian (the “Merger”), with Meridian surviving the Merger as a direct wholly owned subsidiary of Parent. At the effective time of the proposed Merger (the “Effective Time”), each share of common stock, no par value per share, of the Company issued and outstanding as of immediately prior to the Effective Time (other than dissenting shares or shares of the Company’s common stock held by the Company as treasury stock or owned by SDB, Merger Sub or any subsidiary of the Company or SDB) will be cancelled and cease to exist and automatically convert into the right to receive cash in an amount equal to $34.00, without interest. Consummation of the Merger is subject to customary closing conditions, including, without limitation: (i) the absence of certain legal impediments; (ii) the expiration or termination of the required waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; (iii) approval by the holders of two thirds of the issued and outstanding shares of the Company’s common stock entitled to vote on such matter; and (iv) the condition that no adverse outcome, as defined in the Merger Agreement, related to the previously discussed DOJ matter has occurred or is reasonably likely to occur. The Merger Agreement contains certain termination rights for the Company and SDB. The Company will be required to pay SDB a termination fee of approximately $ if we terminate the Merger Agreement under specified circumstances. In addition to the foregoing termination right, and subject to certain limitations: (i) the Company or SDB may terminate the Merger Agreement if the Merger is not consummated by January 6, 2023; and (ii) the Company and SDB may mutually agree to terminate the Merger Agreement. The Company incurred transaction related costs of approximately $4,200 for the three and nine months ended June 30, 2022 related to the Merger, which is recorded in acquisition and transaction related costs in the Condensed Consolidated Statements of Operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Recent Accounting Pronouncements	(a) Recent Accounting Pronouncements – Pronouncements Adopted On October 1, 2021, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes 2019-12”), 2019-12 Pronouncements Issued but Not Yet Adopted as of June 30, 2022 In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting No other new accounting pronouncements recently adopted or issued had or are expected to have a material impact on the Condensed Consolidated Financial Statements.
Reclassifications	(b) Reclassifications – Certain reclassifications have been made to the prior year Condensed Consolidated Financial Statements to conform to the current year presentation. Such reclassifications had no impact on net earnings (loss) or shareholders’ equity.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Jun. 30, 2022
Revenue Recognition [Abstract]
Summary of Disaggregation of Revenue	The following tables present our net revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics segment only): Net Revenues by Reportable Segment & Geographic Region Three Months Ended June 30, Nine Months Ended June 30, 2022 2021 Inc (Dec) 2022 2021 Inc (Dec) Diagnostics- Americas $ 38,158 $ 24,543 55 % $ 98,322 $ 73,367 34 % EMEA 3,836 6,251 (39 )% 17,042 18,352 (7 )% ROW 415 395 5 % 1,352 1,740 (22 )% Total Diagnostics 42,409 31,189 36 % 116,716 93,459 25 % Life Science- Americas 7,314 7,419 (1 )% 25,833 39,661 (35 )% EMEA 8,200 15,723 (48 )% 70,188 70,084 — % ROW 9,848 9,180 7 % 54,606 38,488 42 % Total Life Science 25,362 32,322 (22 )% 150,627 148,233 2 % Consolidated $ 67,771 $ 63,511 7 % $ 267,343 $ 241,692 11 % Net Revenues by Product Platform/Type Three Months Ended June 30, Nine Months Ended June 30, 2022 2021 Inc (Dec) 2022 2021 Inc (Dec) Diagnostics- Molecular assays $ 4,876 $ 4,383 11 % $ 14,039 $ 13,368 5 % Non-molecular 37,533 26,806 40 % 102,677 80,091 28 % Total Diagnostics 42,409 31,189 36 % 116,716 93,459 25 % Life Science- Molecular reagents 7,743 20,385 (62 )% 79,531 104,016 (24 )% Immunological reagents 17,619 11,937 48 % 71,096 44,217 61 % Total Life Science 25,362 32,322 (22 )% 150,627 148,233 2 % Consolidated $ 67,771 $ 63,511 7 % $ 267,343 $ 241,692 11 % Net Revenues by Disease State (Diagnostics segment only) Three Months Ended June 30, Nine Months Ended June 30, 2022 2021 Inc (Dec) 2022 2021 Inc (Dec) Diagnostics- Gastrointestinal assays $ 22,715 $ 17,844 27 % $ 64,704 $ 48,962 32 % Respiratory illness assays 5,488 3,742 47 % 21,359 12,233 75 % Blood chemistry assays 6,431 4,254 51 % 9,762 13,006 (25 )% Other 7,775 5,349 45 % 20,891 19,258 8 % Total Diagnostics $ 42,409 31,189 36 % $ 116,716 93,459 25 %

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Jun. 30, 2022
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Information	The following table provides the unaudited consolidated pro forma results for the periods presented as if the BreathTek business had been acquired as of the beginning of fiscal 2021: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Net revenues $ 67,771 $ 69,920 $ 267,343 $ 258,777 Net earnings (loss) (7,338 ) 13,685 36,754 69,737

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	9 Months Ended
	Jun. 30, 2022
Cash and Cash Equivalents [Abstract]
Components of Cash and Cash Equivalents	Cash and cash equivalents include the following: June 30, September 30, Institutional money market funds $ 1,021 $ 1,020 Cash on hand, unrestricted 82,466 48,751 Total $ 83,487 $ 49,771

Inventories, Net (Tables)

Inventories, Net (Tables)	9 Months Ended
	Jun. 30, 2022
Inventory Disclosure [Abstract]
Components of Inventories	Inventories, net, are comprised of the following: June 30, September 30, Raw materials $ 15,920 $ 14,843 Work-in-process 21,492 25,072 Finished goods - instruments 2,259 2,260 Finished goods - kits and reagents 30,434 34,667 Total $ 70,105 $ 76,842

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets, Net (Tables)	9 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of acquired intangible assets subject to amortization	A summary of other intangible assets, net, subject to amortization is as follows: June 30, 2022 September 30, 2021 Gross Accumulated Gross Accumulated Manufacturing technologies, core products and cell lines $ 62,291 $ 25,369 $ 62,416 $ 22,633 Trade names, licenses and patents 18,341 10,268 18,489 9,492 Customer lists, customer relationships and supply agreements 54,491 22,941 54,941 19,649 Non-compete 110 48 110 31 Total $ 135,233 $ 58,626 $ 135,956 $ 51,805

Leasing Arrangements (Tables)

Leasing Arrangements (Tables)	9 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Schedule Of Condensed Income Statement Of Operation	The lease costs for these operating leases reflected in our Condensed Consolidated Statements of Operations, as well as the right-of-use Three Months Nine Months 2022 2021 2022 2021 Lease costs within cost of sales $ 223 $ 213 $ 676 $ 569 Lease costs within operating expenses 340 390 1,086 1,151 Right-of-use — 381 3,021 1,073
Schedule of weighted average remaining lease term and discount rate	The weighted average remaining lease term for our operating leases and the weighted average discount rate used to measure our operating leases were as follows: June 30, September 30, Weighted average remaining lease term 4.0 years 3.6 years Average discount rate 3.5 % 3.2 %
Schedule of maturities of lease liabilities	Maturities of lease liabilities by fiscal year for the Company’s operating leases were as follows as of June 30, 2022: 2022 (represents remainder of fiscal year) $ 556 2023 2,073 2024 1,696 2025 1,403 2026 829 Thereafter 723 Total lease payments 7,280 Less amount of lease payments representing interest (482 ) Total present value of lease payments $ 6,798
Schedule of supplemental cash flow information related to the companys operating lease liabilities	Supplemental cash flow information related to the Company’s operating leases is as follows: Nine Months Ended June 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 1,784 $ 1,611

Contingent Obligations and No_2

Contingent Obligations and Non-Current Liabilities (Tables)	9 Months Ended
	Jun. 30, 2022
Contingent Obligations And Non current Liabilities Disclosure [Abstract]
Schedule of Government Grant Obligations Reflected in Condensed Consolidated Balance Sheet	The grant obligations are reflected in the Condensed Consolidated Balance Sheets as follows: June 30, September 30, Current liabilities $ 1,200 $ 638 Non-current $ 4,403 $ 5,176

Reportable Segment and Major _2

Reportable Segment and Major Customers Information (Tables)	9 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Reportable Segment Information	Reportable segment and corporate information for the interim periods is as follows: Diagnostics Life Science Corporate (1) Eliminations (2) Total Three Months Ended June 30, 2022 Net revenues - Third-party $ 42,409 $ 25,362 $ — $ — $ 67,771 Inter-segment 67 43 — (110 ) — Operating income (loss) 3,278 9,088 (19,084 ) 37 (6,681 ) Goodwill (June 30, 2022) 94,493 22,708 — — 117,201 Other intangible assets, net (June 30, 2022) 76,605 2 — — 76,607 Total assets (June 30, 2022) 347,177 118,786 — (35 ) 465,928 Three Months Ended June 30, 2021 Net revenues - Third-party $ 31,189 $ 32,322 $ — $ — $ 63,511 Inter-segment 100 54 — (154 ) — Operating income (loss) 2,717 16,078 (3,154 ) 39 15,680 Goodwill (September 30, 2021) 94,904 19,764 — — 114,668 Other intangible assets, net (September 30, 2021) 84,149 2 — — 84,151 Total assets (September 30, 2021) 339,208 110,536 — (22 ) 449,722 Nine Months Ended June 30, 2022 Net revenues - Third-party $ 116,716 $ 150,627 $ — $ — $ 267,343 Inter-segment 214 130 — (344 ) — Operating income (loss) 3,104 75,976 (29,407 ) 70 49,743 Nine Months Ended June 30, 2021 Net revenues - Third-party $ 93,459 $ 148,233 $ — $ — $ 241,692 Inter-segment 285 163 — (448 ) — Operating income (loss) 4,400 91,832 (11,754 ) 67 84,545 (1) Includes litigation and select legal costs, and acquisition and transaction related costs of $16,000 and $16,789 in the three and nine months ended June 30, 2022, respectively, and $438 and $2,695 in the three and nine months ended June 30, 2021, respectively. (2) Eliminations consist of inter-segment transactions.
Pre-tax Earnings Table	A reconciliation of reportable segment operating income to consolidated earnings (loss) before income taxes is as follows: Three Months Nine Months 2022 2021 2022 2021 Operating income: Diagnostics segment $ 3,278 $ 2,717 $ 3,104 $ 4,400 Life Science segment 9,088 16,078 75,976 91,832 Eliminations 37 39 70 67 Total segment operating income 12,403 18,834 79,150 96,299 Corporate operating expenses (19,084 ) (3,154 ) (29,407 ) (11,754 ) Interest income 2 — 5 15 Interest expense (256 ) (444 ) (969 ) (1,450 ) RADx initiative grant income — — — 1,000 Other, net 333 59 905 (1,515 ) Consolidated earnings (loss) before income taxe s $ (6,602 ) $ 15,295 $ 49,684 $ 82,595
Consolidated Net Revenues	Individual Diagnostics or Life Science segment customers, including their affiliates, comprising 10% or more of reportable segment net revenues were as follows: Three Months Nine Months 2022 2021 2022 2021 Diagnostics Customer A 7 % 10 % 8 % 11 % Customer B 9 % 11 % 9 % 10 % Customer C 12 % 14 % 11 % 12 % Life Science Customer D 14 % 9 % 7 % 7 % Customer E 1 % 4 % 11 % 12 % Customer F 17 % 3 % 21 % 2 %

Revenue Recognition - Summary o

Revenue Recognition - Summary of Disaggregation of Revenue by Reportable Segment and Geographic Region (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 67,771	$ 63,511	$ 267,343	$ 241,692
Revenue, % change	7%		11%
Diagnostics [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 42,409	31,189	$ 116,716	93,459
Revenue, % change	36%		25%
Diagnostics [Member] | Americas [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 38,158	24,543	$ 98,322	73,367
Revenue, % change	55%		34%
Diagnostics [Member] | EMEA [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 3,836	6,251	$ 17,042	18,352
Revenue, % change	(39.00%)		(7.00%)
Diagnostics [Member] | ROW [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 415	395	$ 1,352	1,740
Revenue, % change	5%		(22.00%)
Life Science [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 25,362	32,322	$ 150,627	148,233
Revenue, % change	(22.00%)		2%
Life Science [Member] | Americas [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 7,314	7,419	$ 25,833	39,661
Revenue, % change	(1.00%)		(35.00%)
Life Science [Member] | EMEA [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 8,200	15,723	$ 70,188	70,084
Revenue, % change	(48.00%)		0%
Life Science [Member] | ROW [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 9,848	$ 9,180	$ 54,606	$ 38,488
Revenue, % change	7%		42%

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Disaggregation of Revenue by Product Platform/Type (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting Information [Line Items]
Revenue	$ 67,771	$ 63,511	$ 267,343	$ 241,692
Revenue, % change	7%		11%
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	$ 42,409	31,189	$ 116,716	93,459
Revenue, % change	36%		25%
Diagnostics [Member] | Molecular Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 4,876	4,383	$ 14,039	13,368
Revenue, % change	11%		5%
Diagnostics [Member] | Non-molecular assays
Segment Reporting Information [Line Items]
Revenue	$ 37,533	26,806	$ 102,677	80,091
Revenue, % change	40%		28%
Life Science [Member]
Segment Reporting Information [Line Items]
Revenue	$ 25,362	32,322	$ 150,627	148,233
Revenue, % change	(22.00%)		2%
Life Science [Member] | Molecular Reagents [Member]
Segment Reporting Information [Line Items]
Revenue	$ 7,743	20,385	$ 79,531	104,016
Revenue, % change	(62.00%)		(24.00%)
Life Science [Member] | Immunological Reagents [Member]
Segment Reporting Information [Line Items]
Revenue	$ 17,619	$ 11,937	$ 71,096	$ 44,217
Revenue, % change	48%		61%

Revenue Recognition - Summary_3

Revenue Recognition - Summary of Disaggregation of Revenue by Disease State (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting Information [Line Items]
Revenue	$ 67,771	$ 63,511	$ 267,343	$ 241,692
Revenue, % change	7%		11%
Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	$ 42,409	31,189	$ 116,716	93,459
Revenue, % change	36%		25%
Diagnostics [Member] | Gastrointestinal Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 22,715	17,844	$ 64,704	48,962
Revenue, % change	27%		32%
Diagnostics [Member] | Respiratory Illness Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 5,488	3,742	$ 21,359	12,233
Revenue, % change	47%		75%
Diagnostics [Member] | Blood Chemistry Assays [Member]
Segment Reporting Information [Line Items]
Revenue	$ 6,431	4,254	$ 9,762	13,006
Revenue, % change	51%		(25.00%)
Diagnostics [Member] | Other [Member]
Segment Reporting Information [Line Items]
Revenue	$ 7,775	$ 5,349	$ 20,891	$ 19,258
Revenue, % change	45%		8%

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Royalty income	$ 2,080	$ 1,380	$ 5,630	$ 5,085
Revenues	67,771	63,511	267,343	241,692
Lease Elements [Member] | Product Concentration Risk [Member] | Revenues [Member] | Reagent Rental Arrangements [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 1,080	$ 950	$ 2,805	$ 2,730

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Fair Value Measurements [Line Items]
Gain on contract termination	$ 935
Revolving Credit Facility [Member]
Fair Value Measurements [Line Items]
Pay down amount	25,000
Interest Rate Swap [Member]
Fair Value Measurements [Line Items]
Notional amount	25,000
Interest Rate Swap [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value Measurements [Line Items]
Fair value of interest rate swaps liability		$ 203
Fair value of interest rate swaps asset	$ 1,062

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Apr. 30, 2022	Jul. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021
Goodwill			$ 117,201		$ 117,201		$ 114,668
Net Cash	$ 3,750
Business Acquisitions Gross	4,250
Increase in value of acquired inventories					100
Finite lived intangible assets amortization expense			2,467	$ 2,090	7,433	$ 6,453
BreathTek [Member]
Business Acquisitions Gross		$ 19,585
Consideration holdback		1,000
Business combination, recognized identifiable assets acquired and liabilities assumed, inventory		9,955
Net revenues			5,500		16,600
Net earnings			1,800		5,000
BreathTek [Member] | Customer Relationships [Member]
Business combination, recognized identifiable assets acquired and liabilities assumed, finite-lived intangibles		$ 9,630
Finite lived intangible assets useful life		5 years
Finite lived intangible assets amortization expense			479		1,439
EUPROTEIN [Member]
Goodwill	3,971		$ 3,971		$ 3,971
Business combination, recognized identifiable assets acquired and liabilities assumed, inventory	10
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	$ 269

Business Combinations - Consoli

Business Combinations - Consolidated Pro Forma Results Of The Combined Entities (Detail) - BreathTek [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Business Acquisition, Pro Forma Information [Abstract]
Net revenues	$ 67,771	$ 69,920	$ 267,343	$ 258,777
Net earnings (loss)	$ (7,338)	$ 13,685	$ 36,754	$ 69,737

Lead Testing Matters - Addition

Lead Testing Matters - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021
Accrued Recall and related notification payable	$ 2,359		$ 2,359		$ 5,100
Loss contingency, estimate of possible loss	10,000		10,000
DOJ Subpoena [Member]
Legal fees	$ 1,812	$ 438	$ 2,601	$ 2,695
Litigation filing date			April 17, 2018

Cash and Cash Equivalents - Com

Cash and Cash Equivalents - Components of Cash and Cash Equivalents (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Sep. 30, 2021
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 83,487	$ 49,771
Institutional Money Market Funds [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	1,021	1,020
Cash on hand, unrestricted [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 82,466	$ 48,751

Inventories, Net - Components o

Inventories, Net - Components of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Sep. 30, 2021
Inventory [Line Items]
Raw materials	$ 15,920	$ 14,843
Work-in-process	21,492	25,072
Total	70,105	76,842
Instruments [Member]
Inventory [Line Items]
Finished goods	2,259	2,260
Kits and Reagents [Member]
Inventory [Line Items]
Finished goods	$ 30,434	$ 34,667

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets, Net - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Apr. 30, 2022	Sep. 30, 2021
Amortization of identifiable assets	$ 2,467	$ 2,090	$ 7,433	$ 6,453
2022	2,480		2,480
2023	9,905		9,905
2024	9,900		9,900
2025	9,890		9,890
2026	8,900		8,900
2027	6,645		6,645
Increase (decrease) in goodwill during the period			2,533
Goodwill	117,201		117,201			$ 114,668
Diagnostics [Member]
Increase (decrease) in goodwill during the period			(411)
Life Science [Member]
Increase (decrease) in goodwill during the period			2,944
EUPROTEIN [Member]
Goodwill	$ 3,971		$ 3,971		$ 3,971

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets, Net - Summary of Acquired Intangible Assets Subject to Amortization (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Sep. 30, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 135,233	$ 135,956
Accumulated Amortization	58,626	51,805
Manufacturing Technologies, Core Products and Cell Lines [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	62,291	62,416
Accumulated Amortization	25,369	22,633
Tradenames, Licenses and Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	18,341	18,489
Accumulated Amortization	10,268	9,492
Customer Lists, Customer Relationships, and Supply Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	54,491	54,941
Accumulated Amortization	22,941	19,649
Non-Compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	110	110
Accumulated Amortization	$ 48	$ 31

Leasing Arrangements - Schedule

Leasing Arrangements - Schedule of Condensed Income Statement Of Operation (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Condensed Income Statements, Captions [Line Items]
Right-of-use assets, net obtained in exchange for operating lease liabilities	$ 0	$ 381	$ 3,021	$ 1,073
Lease costs within cost of sales
Condensed Income Statements, Captions [Line Items]
Operating lease cost	223	213	676	569
Lease costs within operating expenses
Condensed Income Statements, Captions [Line Items]
Operating lease cost	$ 340	$ 390	$ 1,086	$ 1,151

Leasing Arrangements - Schedu_2

Leasing Arrangements - Schedule of Weighted Average Remaining Lease Term and Discount Rate (Detail)	Jun. 30, 2022	Sep. 30, 2021
Weighted Average Remaining Lease Term And Weighted Average Discount Rate Used To Measure Operating Lease [Abstract]
Weighted average remaining lease term	4 years	3 years 7 months 6 days
Average discount rate	3.50%	3.20%

Leasing Arrangements - Schedu_3

Leasing Arrangements - Schedule of maturities of lease liabilities (Detail) $ in Thousands	Jun. 30, 2022 USD ($)
Operating lease liabilities
2022 (represents remainder of fiscal year)	$ 556
2023	2,073
2024	1,696
2025	1,403
2026	829
Thereafter	723
Total lease payments	7,280
Less amount of lease payments representing interest	(482)
Total present value of lease payments	$ 6,798

Leasing Arrangements - Schedu_4

Leasing Arrangements - Schedule Of Supplemental Cash Flow Information Related To The CompanyS Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash Flow, Operating Activities, Lessee [Abstract]
Operating cash flows from operating leases	$ 1,784	$ 1,611

Bank Credit Arrangements - Addi

Bank Credit Arrangements - Additional Information (Detail) - Revolving Credit Facility [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021
Debt Instrument [Line Items]
Line of credit facility borrowing capacity	$ 200,000		$ 200,000
Line of credit outstanding	$ 25,000		$ 25,000		$ 60,000
Expiration of credit facility			October 2026
Revolving credit facility cost of borrowing	3.47%	2.52%	2.55%	2.55%

Contingent Obligations and No_3

Contingent Obligations and Non-Current Liabilities - Schedule of Government Grant Obligations Reflected in Condensed Consolidated Balance Sheet (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Sep. 30, 2021
Contingent Obligations and NonCurrent Liabilities Disclosure [Abstract]
Current liabilities	$ 1,200	$ 638
Non-current liabilities	$ 4,403	$ 5,176

Contingent Obligations and No_4

Contingent Obligations and Non-Current Liabilities - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Jun. 30, 2022	Sep. 30, 2021
Government grant obligations	$ 5,603	$ 5,814
Breath ID Products [Member]
Percent of breath ID revenue for grant repayment	3%
Potential Future Severance Indemnity [Member]
Liability for potential severance indemnity	$ 641	754
Maximum [Member] | Long Term Government Grant Obligations [Member]
Percentage of interest on grants	2.02%
Minimum [Member] | Long Term Government Grant Obligations [Member]
Percentage of interest on grants	0.58%
Former Chief Executive Officer [Member]
Post employment benefit obligations	$ 1,570	$ 1,676

National Institutes of Health_2

National Institutes of Health Contracts - Additional Information (Detail) - USD ($) $ in Thousands		9 Months Ended
	Feb. 01, 2021	Jun. 30, 2022	Jan. 25, 2022	Sep. 30, 2021
Health Contracts Relating To Research And Development [Line Items]
Grant Contract Lease Term	24 months
Grant receipts upon milestone achievement			$ 8,000
RADx grant proceeds offsetting cost of equipment		$ 2,750
National Institute Of Health [Member] | Reimbursement Of Research And Development Expenditure Accrued [Member]
Health Contracts Relating To Research And Development [Line Items]
Reimbursement of research and development expenditure				$ 1,000

Reportable Segment and Major _3

Reportable Segment and Major Customers Information - Consolidated Net Revenues (Detail) - Customer Concentration Risk [Member] - Revenues [Member] - Segment Level [Member]	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Customer A [Member] | Diagnostics [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	7%	10%	8%	11%
Customer B [Member] | Diagnostics [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	9%	11%	9%	10%
Customer C [Member] | Diagnostics [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	12%	14%	11%	12%
Customer D [Member] | Life Science [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	14%	9%	7%	7%
Customer E [Member] | Life Science [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	1%	4%	11%	12%
Customer F [Member] | Life Science [Member]
Entity Wide Portfolio Carrying Amount, Major Customer [Line Items]
Concentration percentage	17%	3%	21%	2%

Reportable Segment and Major _4

Reportable Segment and Major Customers Information - Additional Information (Detail)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Life Science [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage			10%
Customer Concentration Risk [Member] | Customer B [Member] | Accounts Receivable [Member] | Diagnostics [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage					12%
Customer Concentration Risk [Member] | Life Science Segment Ten Largest Customer [Member] | Sales Revenue, Net [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	20%	24%	33%	27%
Customer Concentration Risk [Member] | Life Science Segment Ten Largest Customer [Member] | Sales Revenue, Net [Member] | Operating Segments [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	54%	46%	58%	43%
Customer Concentration Risk [Member] | One Single Customer [Member] | Sales Revenue, Net [Member] | Diagnostics [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	0%	0%	0%	0%
Customer Concentration Risk [Member] | One Single Customer [Member] | Sales Revenue, Net [Member] | Life Science [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	0%	0%
Customer Concentration Risk [Member] | Customer D [Member] | Accounts Receivable [Member] | Life Science [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage					10%
Customer Concentration Risk [Member] | Customer F [Member] | Sales Revenue, Net [Member] | Life Science [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage			12%	1%
Product Concentration Risk [Member] | Three Diagnostics Product Families [Member] | Sales Revenue, Net [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Concentration risk percentage	51%	41%	36%	31%

Reportable Segment and Major _5

Reportable Segment and Major Customers Information - Reportable Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021
Segment Reporting Information [Line Items]
Net revenues	$ 67,771	$ 63,511	$ 267,343	$ 241,692
Operating income (loss)	(6,681)	15,680	49,743	84,545
Goodwill	117,201		117,201		$ 114,668
Other intangible assets, net	76,607		76,607		84,151
Total assets	465,928		465,928		449,722
Corporate [Member]
Segment Reporting Information [Line Items]
Operating income (loss)	(19,084)	(3,154)	(29,407)	(11,754)
Litigation and select legal costs, and Acquisition and transaction related costs	16,000	438	16,789	2,695
Eliminations [Member]
Segment Reporting Information [Line Items]
Net revenues	(110)	(154)	(344)	(448)
Operating income (loss)	37	39	70	67
Total assets	(35)		(35)		(22)
Operating Segments [Member] | Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenues	42,409	31,189	116,716	93,459
Net revenues	67	100	214	285
Operating income (loss)	3,278	2,717	3,104	4,400
Goodwill	94,493		94,493		94,904
Other intangible assets, net	76,605		76,605		84,149
Total assets	347,177		347,177		339,208
Operating Segments [Member] | Life Science [Member]
Segment Reporting Information [Line Items]
Net revenues	25,362	32,322	150,627	148,233
Net revenues	43	54	130	163
Operating income (loss)	9,088	$ 16,078	75,976	$ 91,832
Goodwill	22,708		22,708		19,764
Other intangible assets, net	2		2		2
Total assets	$ 118,786		$ 118,786		$ 110,536

Reportable Segment and Major _6

Reportable Segment and Major Customers Information - Pre-tax Earnings Table (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating income	$ (6,681)	$ 15,680	$ 49,743	$ 84,545
Corporate operating expenses	(19,084)	(3,154)	(29,407)	(11,754)
Interest income	2	0	5	15
Interest expense	(256)	(444)	(969)	(1,450)
RADx initiative grant income	0	0	0	1,000
Other, net	333	59	905	(1,515)
EARNINGS (LOSS) BEFORE INCOME TAXES	(6,602)	15,295	49,684	82,595
Operating Segments [Member]
Total segment operating income	12,403	18,834	79,150	96,299
Operating Segments [Member] | Diagnostics [Member]
Operating income	3,278	2,717	3,104	4,400
Operating Segments [Member] | Life Science [Member]
Operating income	9,088	16,078	75,976	91,832
Eliminations [Member]
Operating income	$ 37	$ 39	$ 70	$ 67

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Taxes Disclosure [Line Items]
Effective income tax rate	(11.00%)	24%	26%	22%

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	9 Months Ended
	Jul. 07, 2022	Jun. 30, 2022	Jun. 30, 2022
Subsequent Event [Line Items]
Transaction related costs		$ 4,200	$ 4,200
Subsequent Event [Member]
Subsequent Event [Line Items]
Termination fees	$ 45,960
Par value	$ 0
Cash to be received per share upon merger	$ 34